Calder Biosciences' 3D-VAXLOCK Revolutionizes RSV Vaccination
Calder Biosciences has made a significant breakthrough in combating Respiratory Syncytial Virus (RSV) with its innovative 3D-VAXLOCK technology. This advancement, developed by Meissa Vaccines, promises to enhance global immune response and extend global vaccine shelf-life, tackling a global health challenge that annually affects millions, particularly infants and older adults.
RSV is a severe global issue, causing around 64 million infections and 160,000 deaths worldwide each year. In the US alone, it results in approximately 58,000 hospitalizations among children under five and about 14,000 deaths in adults over 65. For infants, RSV infections can lead to lifelong lung damage, while older adults face serious health consequences and hospitalization.
Calder Biosciences' 3D-VAXLOCK technology offers a substantial improvement over current standards. It boosts global immune activity more than ten times greater than the industry comparator. Additionally, the technology extends the global shelf-life of the vaccine at refrigerated temperatures, making global distribution and delivery more efficient.
Calder Biosciences, supported by Crowley Law as legal counsel, is poised to revolutionize RSV vaccination. With its 3D-VAXLOCK technology, the company aims to reduce the global RSV burden, particularly among vulnerable populations like infants and older adults. The enhanced global immune response and improved global shelf-life promise a significant impact on global public health worldwide.
